Results based on a 2022 global PatientView survey.
Horizon Therapeutics plc revealed its ranking of first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. According to PatientView’s 2022 global Corporate Reputation of Pharma survey, Horizon ranked first in 10 of 14 indicators including patient centricity, patient information, integrity, access to medicines, relationships, and services. The survey included 426 patient groups who analyzed 34 pharma and biotech organizations.
“We are honored by the feedback that rare disease patient advocacy groups provided within the PatientView report,” said Matt Flesch, VP, patient advocacy, product communications, Horizon. “Our approach to patient advocacy is to participate, listen and learn, knowing that rare disease patient groups are usually the main catalyst for progress, driving awareness and education, building community, and advancing research toward treatments and cures. From the programs that we support to the initiatives that we create; our belief is that meaningful and appropriate collaboration with patient advocacy groups is core to all our work at Horizon.”
Reference: Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups. BusinessWire. August 23, 2023. Accessed August 24, 2023. https://www.businesswire.com/news/home/20230823744270/en/Horizon-Therapeutics-plc-Ranks-First-in-Overall-Corporate-Reputation-by-Rare-Disease-Patient-Advocacy-Groups
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.